Matthew L Maciejewski1, Xiaojuan Mi2, Lesley H Curtis2, Judy Ng2, Samuel C Haffer2, Bradley G Hammill2. 1. From the Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, NC (M.L.M.); Division of General Internal Medicine, Department of Medicine (M.L.M., L.H.C.) and Duke Clinical Research Institute (X.M., L.H.C., B.G.H.), Duke University Medical Center, Durham, NC; National Committee for Quality Assurance, Washington, DC (J.N.); and Office of Minority Health, US Centers for Medicare and Medicaid Services, Baltimore, MD (S.C.H.). mlm34@duke.edu. 2. From the Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, NC (M.L.M.); Division of General Internal Medicine, Department of Medicine (M.L.M., L.H.C.) and Duke Clinical Research Institute (X.M., L.H.C., B.G.H.), Duke University Medical Center, Durham, NC; National Committee for Quality Assurance, Washington, DC (J.N.); and Office of Minority Health, US Centers for Medicare and Medicaid Services, Baltimore, MD (S.C.H.).
Abstract
BACKGROUND: Despite the persistence of significant disparities, few evaluations examine disparities in laboratory testing by race/ethnicity, age, sex, Medicaid eligibility, and number of chronic conditions for Medicare fee-for-service beneficiaries' newly prescribed medications. In Medicare beneficiaries initiating diuretics or digoxin, this study examined disparities in guideline-appropriate baseline laboratory testing and abnormal laboratory values. METHODS AND RESULTS: To evaluate guideline-concordant testing for serum creatinine and serum potassium within 180 days before or 14 days after the index prescription fill date, we constructed retrospective cohorts from 10 states of 99 711 beneficiaries who had heart failure or hypertension initiating diuretic in 2011 and 8683 beneficiaries who had heart failure or atrial fibrillation initiating digoxin. Beneficiaries initiating diuretics were less likely to have testing if they were non-Hispanic Black (relative risk [RR], 0.99; 95% confidence interval [CI], 0.98-0.99) than non-Hispanic White. Beneficiaries initiating diuretics and beneficiaries initiating digoxin were more likely to have testing if they had multiple chronic conditions relative to 0 to 1 conditions. Beneficiaries initiating diuretics with laboratory values were more likely to have an abnormal serum creatinine value at baseline if they were non-Hispanic Black (RR, 2.57; 95% CI, 1.91-3.44), other race (RR, 2.11; 95% CI, 1.08-4.10), or male (RR, 2.75; 95% CI, 2.14-3.52) or an abnormal serum potassium value if they were aged ≥76 years (RR, 1.29; 95% CI, 1.09-1.51) or male (RR, 1.17; 95% CI, 1.03-1.33). CONCLUSIONS: Testing rates were consistently high, so there were negligible disparities in guideline-concordant testing of creatinine and potassium after the initiation of digoxin or diuretics by Medicare beneficiaries.
BACKGROUND: Despite the persistence of significant disparities, few evaluations examine disparities in laboratory testing by race/ethnicity, age, sex, Medicaid eligibility, and number of chronic conditions for Medicare fee-for-service beneficiaries' newly prescribed medications. In Medicare beneficiaries initiating diuretics or digoxin, this study examined disparities in guideline-appropriate baseline laboratory testing and abnormal laboratory values. METHODS AND RESULTS: To evaluate guideline-concordant testing for serum creatinine and serum potassium within 180 days before or 14 days after the index prescription fill date, we constructed retrospective cohorts from 10 states of 99 711 beneficiaries who had heart failure or hypertension initiating diuretic in 2011 and 8683 beneficiaries who had heart failure or atrial fibrillation initiating digoxin. Beneficiaries initiating diuretics were less likely to have testing if they were non-Hispanic Black (relative risk [RR], 0.99; 95% confidence interval [CI], 0.98-0.99) than non-Hispanic White. Beneficiaries initiating diuretics and beneficiaries initiating digoxin were more likely to have testing if they had multiple chronic conditions relative to 0 to 1 conditions. Beneficiaries initiating diuretics with laboratory values were more likely to have an abnormal serum creatinine value at baseline if they were non-Hispanic Black (RR, 2.57; 95% CI, 1.91-3.44), other race (RR, 2.11; 95% CI, 1.08-4.10), or male (RR, 2.75; 95% CI, 2.14-3.52) or an abnormal serum potassium value if they were aged ≥76 years (RR, 1.29; 95% CI, 1.09-1.51) or male (RR, 1.17; 95% CI, 1.03-1.33). CONCLUSIONS: Testing rates were consistently high, so there were negligible disparities in guideline-concordant testing of creatinine and potassium after the initiation of digoxin or diuretics by Medicare beneficiaries.
Authors: Daniel S Budnitz; Daniel A Pollock; Kelly N Weidenbach; Aaron B Mendelsohn; Thomas J Schroeder; Joseph L Annest Journal: JAMA Date: 2006-10-18 Impact factor: 56.272
Authors: Adrianne C Feldstein; David H Smith; Nancy Perrin; Xiuhai Yang; Mary Rix; Marsha A Raebel; David J Magid; Steven R Simon; Stephen B Soumerai Journal: Arch Intern Med Date: 2006-09-25
Authors: Larry A Allen; Susan M Shetterly; Pamela N Peterson; Jerry H Gurwitz; David H Smith; David W Brand; Diane L Fairclough; John S Rumsfeld; Frederick A Masoudi; David J Magid Journal: Circ Heart Fail Date: 2013-11-26 Impact factor: 8.790
Authors: Thomas L Fisher; Deborah L Burnet; Elbert S Huang; Marshall H Chin; Kathleen A Cagney Journal: Med Care Res Rev Date: 2007-10 Impact factor: 3.929
Authors: Marshall H Chin; Amanda R Clarke; Robert S Nocon; Alicia A Casey; Anna P Goddu; Nicole M Keesecker; Scott C Cook Journal: J Gen Intern Med Date: 2012-08 Impact factor: 5.128
Authors: Barbara Starfield; Klaus W Lemke; Robert Herbert; Wendy D Pavlovich; Gerard Anderson Journal: Ann Fam Med Date: 2005 May-Jun Impact factor: 5.707